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ABSTRACT
Human topoisomerase II (topo II) is the cellular target
foranumberofwidelyusedantitumoragents,suchas
etoposide (VP16). These agents ‘poison’ the enzyme
and induce it to generate DNA breaks that are lethal
to the cell. Topo II-targeted drugs show a limited
sequence preference, triggering double-stranded
breaks throughout the genome. Circumstantial
evidencestronglysuggeststhatsomeofthesebreaks
induce chromosomal translocations that lead to
specific types of leukaemia (called treatment-related
or secondary leukaemia). Therefore, efforts are
ongoing to decrease these secondary effects. An
interesting option is to increase the sequence-
specificity of topo II-targeted drugs by attaching
them to triplex-forming oligonucleotides (TFO) that
bind to DNA in a highly sequence-specific manner.
Here five derivatives of VP16 were attached to
TFOs.TheactivetopoIIpoisons,oncelinked,induced
cleavage13–14bpfromthetriplexendwherethedrug
wasattached.Theuseoftriple-helicalDNAstructures
offers an efficient strategy for targeting topo II-
mediated cleavage to DNA specific sequences.
Finally, drug–TFO conjugates are useful tools to
investigate the mechanistic details of topo II
poisoning.
INTRODUCTION
Human topoisomerase II (topo II) is a ubiquitous nuclear
enzyme involved in the control of DNA topology (1–4).
During the catalytic cycle, the enzyme transiently cleaves
dsDNA, passes an intact double helix through the break and
reseals it. Vertebrates contain two isoforms of the enzyme,
topo IIa and b (1). Topo IIa levels increase during cell
proliferation and this enzyme appears to be the isoform
involved in mitosis (2). To maintain DNA integrity during
the strand passage event, the enzyme, a homodimer, forms
a covalent 50-phosphotyrosyl adduct between the catalytic
Tyr
804 of each monomer and a strand of the duplex. This
covalent enzyme-cleaved DNA complex is referred to as
the cleavage complex (1–4). Under normal physiological
conditions, the DNA cleavage and ligation reactions of topoi-
somerase are tightly coordinated and the covalent intermediate
is bearly detectable. However, a number of drugs, such as
the antitumor etoposide (VP16) [for reviews (4–9)], block
the religation step after DNA cleavage. As a result, they
dramatically increase levels of topo II–DNA cleavage
complexes (DNA/topo II/drug ternary complex). Although
transient in nature, cleavage complexes are converted to
permanent DNA strand breaks when nucleic acid tracking
systems attempt to traverse the protein roadblock in the
genetic material. The resulting DNA strand breaks initiate
multiple recombination/repair pathways and can trigger cell
death pathways (10,11).
Despite the wide use of topo II-targeted drugs as antitumor
agents, several limitations hamper their beneﬁts. Toxicity is
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doi:10.1093/nar/gkl126one limiting factor, and it is partially related to the fact that
topo II poisons stimulate DNA cleavage at multiple sites along
the double helix with a limited sequence preference (one or
two bases around the cleavage site, e.g. C/T-1# for VP16).
Moreover, the use of VP16 and other topo II poisons has
been linked to the initiation of speciﬁc types of leukaemia
that correlate with the generation of enzyme-mediated clea-
vage within the MLL gene (12–15). Therefore, an option to
improve these agents would be to increase their sequence-
speciﬁcity and to direct DNA cleavage only on a chosen target
gene, involved, e.g. in tumor formation and/or maintenance.
The ﬁrst attempt to increase the speciﬁcity of a
topoisomerase-targeted drug used topo I poisons as a model
system (16–18). These drugs act by stabilizing the topo I-DNA
cleavage complex and increasing cleavage on one strand of the
double helix (19). Sequence-speciﬁcity was enhanced consid-
erably by linkage of topo I posions to a DNA recognition
element, such as a triple helix-forming oligonucleotide
(TFO). Camptothecin and rebeccamycin derivatives coval-
ently linked to a TFO induce topo I-mediated DNA cleavage
selectively near the triplex site (16–18).
In contrast, no speciﬁc targeting of the drug was observed
upon attachment of amsacrine, a clinically-relevant topo II
poison, to a TFO; rather, the only sequence-speciﬁc effect
of the drug–TFO-conjugate on topo II binding and DNA
cleavage was attributed to the changes in local DNA structure
induced by the formation of the triple helix (20). Whether
this lack of success resulted from the bulkiness of the enzyme,
the geometry of the conjugate, or the local DNA sequence
could not be determined. However, since amsacrine is a DNA
intercalator, it could have been sequestered at the triplex/
duplex junction and thus been unavailable for the enzyme.
Therefore, to further investigate the potential of TFO-
poisons to selectively induce topo II-mediated DNA cleavage,
several biologically active derivatives of VP16 were synthe-
sized and linked to olignucleotides via terminal amino groups
on the drug (21–23). Results reported in this work indicate that
the conjugation of VP16 derivatives to TFOs is able to direct
the action of topo II poisons and speciﬁcally induce DNA
cleavage 14 bp from the terminus of the triplex site.
MATERIALS AND METHODS
Materials
1H NMR spectra were recorded in chloroform-d or
methanol-d4, on a Bruker AC spectrometer (300 MHz). For
all oligonucleotides (ODNs) conjugates, mass determination
was accomplished by electrospray ionization on a Q-STAR
pulsar I (Appleura) and high-performance liquid chromatogra-
phy (HPLC) puriﬁcations were performed upon Agilent 1100
using a Waters XTerra MS  C18 reversed phase column (4.6 ·
50 mm, 2.5 mm). Absorbance spectrophotometry was per-
formed on an Uvikon 860 (Kontron).
All chemicals were purchased from Sigma–Aldrich, ICRF-
193 from Euromedex. All solvents were of analytical grade.
Analogs of VP16 1, 2, 3 and 4 were synthesized as previously
described (22,23) or 5 and 6 as described below. VP16 and
analogs were dissolved in dimethylsulfoxide at 5 mM and then
dilutedfurther with water.Theywereattached tothe TFOs end
as described in Figure 1.
Topo II
Human topo IIa was purchased from NuVentures Ltd (UK)
and mutant topo II Y805F was prepared as described
previously (24).
Synthesis of 4-b-(4-Boc-aminomethylphenyl)amido-40-
O-demethyl-40-O-(4-azidobenzoyl)-4-
deoxypodophyllotoxin (5)
A solution of Boc-protected 4 was prepared as reported
previously (23) (700 mg, 1.1 mmol) in anhydrous CH2Cl2
(50 ml) under inert atmosphere. p-Azidobenzoylchloride
(235 mg, 1.3 mmol) and triethylamine (8 ml, 1.1 mmol)
were added and the reaction mixture was stirred at room
temperature for 3 h, according to (25). The medium was
then taken up with CH2Cl2 and water. The organic phase
was washed with H2O( 3· 50 ml), then dried (MgSO4) and
ﬁltered. This compound was puriﬁed by silica gel chromato-
graphy using CH2Cl2/acetone 90:10 to provide pure compo-
und in 68% yield. Rf ¼ 0.66 (CH2Cl2/acetone 90:10),
1H NMR (CDCl3) d: 8.18 (d, 2H, J ¼ 8.6 Hz, PhN3), 7.72
(d, 2H, J ¼ 8.1 Hz, PhCH2NHBoc), 7.33 (d, 2H, J ¼ 8.1 Hz,
PhCH2NHBoc), 7.11 (d, 2H, J ¼ 8.6 Hz, PhN3), 6.81 (s, 1H,
5-H), 6.57 (s, 1H, 8-H), 6.48-6.30 (m, 3H, 4-NH, 20,60-H), 5.98
(d, 2H, J ¼ 4.2 Hz, CH2O2), 5.47-5.39 (m, 1H, 4-H), 4.98
(br s, 1H, NHBOC), 4.66 (d, 1H, J ¼ 4.1 Hz, 1-H), 4.49 (t, 1H,
J ¼ 7.7 Hz, 11a-H), 4.31 (d, 2H, J ¼ 5.6 Hz, CH2NH), 3.87
(t, 1H, J ¼ 4.8 Hz, 11b-H), 3.69 (s, 6H, 30,50-OCH3), 3.10-
2.92 (m, 2H, 2,3-H), 1.44 (s, 9H, Boc); MS (CI) m/z: 795
[M + NH4]
+.
Synthesis of 4-b-(4-aminomethylphenyl)amido-40-O-
demethyl-40-O-(4-azidobenzoyl)-4-
deoxypodophyllotoxin (6)
Triﬂuoroacetic acid (TFA, 400 ml, 5.3 mmol) was added to a
solution of 5 (400 mg, 0.53 mmol) in CH2Cl2 (10 ml). The
reaction mixture was stirred for 5 h and washed with cold
saturated NaHCO3 followed by water until the pH of the
solution was 6–7. The extract was dried over MgSO4 and
concentrated in vacuo at 30 C. The residue was puriﬁed by
silica gel column chromatography using a mixture CH2Cl2/
methanol 9:1 to afford the pure compound in 76% yield.
Rf ¼ 0.45 (CH2Cl2/methanol 9:1),
1H NMR (CD3OD) d: 8.14
(d, 2H, J ¼ 8.5 Hz, PhCH2NH2), 7.88 (d, 2H, J ¼ 8.1 Hz,
PhN3), 7.49 (d, 2H, J ¼ 8.1 Hz, PhN3), 7.21 (d, 2H, J ¼ 8.5 Hz,
PhCH2NH2), 6.86 (s, 1H, 5-H), 6.59 (s, 1H, 8-H), 6.49 (s, 2H,
20,60-H), 5.97 (d, 2H, J ¼ 1.8 Hz, CH2O2), 5.52-5.48 (m, 1H,
4-H), 4.73 (d, 1H, J ¼ 5.2 Hz, 1-H), 4.47 (t, 1H, J ¼ 8.0 Hz,
11a-H), 4.00 (s, 2H, CH2NH), 3.87 (t, 1H, J ¼ 9.8 Hz, 11b-H),
3.69 (s, 6H, 30,50-OCH3), 3.40-3.28 (m, 1H, 2-H), 3.20-
3.12 (m, 1H, 3-H); MS (CI) m/z: 695 [M + NH4]
+.
ODNs
ODNs were purchased from Eurogentec and puriﬁed using
quick spin Sephadex G-25 columns (BioRad). Concentrations
were determined spectrophotometrically at 25 C using molar
extinction coefﬁcients at 260 nm calculated from a nearest-
neighbor model (26). ODN, used as control, has the following
sequence: 50-TTTTMTTTTMMMMMMT-30, where M stands
for 5-methyl-20-deoxycytidine.
Nucleic Acids Research, 2006, Vol. 34, No. 6 1901The nomenclature of the ODNs and conjugates is the
following: the abbreviation TFO is preceded by a number
referring to the length of the ODN and followed, if attached
to the 30 end, or preceded, if attached through the 50 end,
by the letter L (for linker) and the number of atoms in the
linker (L3, ethylene glycol; L18, hexaethylene glycol, L12,
8-[(3-aminopropyl)-(7-carboxyheptyl)amino]octanoic acid),
and ﬁnally, by the denomination of the 40-demethylepipodo-
phyllotoxin derivative. For example, 20TFO-L18-4 stands for
the 20mer TFO linked at its 30 end through the hexaethylene
glycolspacertocompound4.Theorientationofthetriplehelix
is deﬁned as the orientation of the purine-rich strand of the
duplex, the TFO binds in the major groove in an orientation
parallel to the oligopurine strand. All conjugates were synthe-
sized and characterized as described in (23) or as described
below.
Synthesis of 20TFO-L18-6 and 16TFO-L18-6
Azido compound 6 was attached to the terminal phosphate of
the hexaethylene linker at the 30 end of the TFOs according to
the procedures described previously (27). The product was
puriﬁed by HPLC and characterized by ultraviolet (UV)
spectroscopy and mass spectrometry.
16TFO-L18-6 MS (ES
 ) m/z: 6147 [M-H]
  (calc. 6147)
20TFO-L18-6 MS (ES
 ) m/z: 7410 [M-H]
  (calc. 7410)
Figure 1. The sequence of the target duplex and the TFOs, and the chemical structure of the drug–TFO conjugates. The 77 bp duplex target sequence was inserted
betweentheBamHIandEcoRIsitesofpBSK.TheTFOiscomplementarytotheoligopurinestrandoftheduplexandbindsparalleltoit.Thetargetsiteisinboldface
for the 20 nt TFO and is underlined for the 16 nt TFOs. M, 5-methyl-20-deoxycytidine; P, 5-propynyl-20-deoxyuridine. The structures of the VP16 derivatives-TFO
conjugates used in this study are shown. The nomenclature of the conjugates is described in the Materials and Methods.
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The plasmid pBSK was purchased from Promega (USA)
and the 77 bp target duplex was inserted between the
BamHI and EcoRI sites (see Figure 1 for sequence). The
324 bp DNA fragment was prepared by 50 32P-end-labeling
the EcoRI or PvuII/alkaline phosphatase treated plasmid
using [g-
32P]ATP and T4 polynucleotide kinase followed
by treatment with PvuII/EcoRI, yielding a fragment radio-
labeled on the pyrimidine strand (Y) or on the purine
strand (R), respectively. Digestion with NotI instead of
PvuII generated 96 bp DNA fragments, alternatively 50-
radiolabeled on the Y or R strand. A 357mer DNA fragment
was obtained by standard PCR using as alternatively 50-
radiolabeled primers 50-CGAGGTCGACGGTATCGATAA-
30 and 50-CACGACAGGTTTCCCGACTGG-30, a tempera-
ture of annealing of 57 C and Taq I (Promega). The detailed
procedure for isolation and puriﬁcation has been described
previously (28).
Topoisomerase II cleavage assays
The 50 end 96 or 324 bp radiolabeled DNA fragment (50 nM)
and the TFO (at the indicated concentration) were incubated
for 1 h at 30 C in a total volume of 10 ml of 50 mM Tris–HCl
(pH 7.0), 120 mM KCl, 1 mM ATP, 10 mM MgCl2, 0.5 mM
DTT, 0.1 mM EDTA and 30 mg/mlof BSA in order toform the
triplex or in the presence of the drug. Human topo IIa (0.7 U)
was added to the triplex DNA and incubated for 20 min at
30 C. Following ethanol precipitation, samples were sus-
pended in 6 ml of formamide, heated at 90 C for 3 min and
chilled on ice for 4 min, they were then subjected to electro-
phoresis on a denaturing 8% polyacrylamide gel (19:1 acry-
lamide:bisacrylamide) containing7.5 M urea in1·TBE buffer
(50 mM Tris-base, 55 mM boric acid, 1 mM EDTA) for
120 min at 65 W. To quantify the extent of cleavage, gels
were scanned with a Typhoon 9410 (Amersham Biosciences).
DNA cleavage was normalized to the total counts loaded in
each reaction. Experiments were repeated between four and
ten times.
Crosslinking assays
The50 endlabeled357bpDNAfragment(50nM)andtheTFO
(at the indicated concentration) were incubated for 1 h at 30 C
in a total volume of 10 ml of 50 mM Tris–HCl (pH 7.0),
120 mM KCl, 1 mM ATP, 10 mM MgCl2, 0.5 mM DTT,
0.1 mM EDTA and 30 mg/ml of BSA in order to form the
triplex or in the presence of drug. Human topo IIa (0.7 U) was
added to the DNA and incubated for 20 min at 30 C. All
samples were irradiated at 365 nm for 30 min and reaction
products were then treated in one of the three ways. (i) Direct
analysis: samples were precipitated in ethanol. (ii) Piperidine
cleavage reactions: piperidine (100 ml of a 1 M solution)
was added to the reaction products and incubated at 90 C
for 30 min. Piperidine was removed by lyophilization. (iii)
DNase I footprinting: samples were digested with 1 mlo f
DNase I (ﬁnal concentration 0.03 mg/ml, Sigma) diluted in
1 mM MgCl2, 1 mM MnCl2 and 20 mM NaCl (pH 7.3). The
reaction was performed for 3 min at 20 C and was stopped by
ethanol precipitation.
All samples subsequently were treated as in the topo II
cleavage assay. DNA crosslinking was normalized to the
total counts loaded in each reaction.
Competition experiments
The 50 end 357 bp radiolabeled DNA fragment (50 nM) was
incubated as above in the presence of the TFO (at the indicated
concentration) in order to form the triplex or in the presence of
the drug. Human topo IIa (0.7 U) was added to the samples
and incubated at 30 C. After 5 min incubation, increasing
concentrations (from 50 mM to 1 mM) of competitor (ICRF
193 or VP16) were added, and the incubation followed for
other 15 min at 30 C. These samples, irradiated or not, were
precipitated in ethanol and suspended in 6 ml of formamide.
They were then subjected to electrophoresis on a denaturing
8% polyacrylamide gel (19:1 acrylamide:bisacrylamide)
containing 7.5 M urea in 1· TBE buffer for 120 min at
65 W and analyzed as above. Experiments were repeated
between four and ten times.
RESULTS
Experimental design
The target duplex contains a 20 bp oligopyrimidine 
oligopurine sequence suitable for triplex formation (boldface
in Figure 1). A 16mer triplex-forming ODN, 16TFO, contain-
ing 5-methyl-20-deoxycytidine (M) and 5-propynyl-20-
deoxyuridine (P) was used in order to form a stable
pyrimidine-motif triple helix at pH 7.0 (underlined sequence)
(29–31). In order to verify the positioning of the drug by the
triplex at different sites, the 16mer TFO was extended by 4 nt
at its 30 end to obtain 20TFO that forms a stable triple helix on
the entire target sequence (in boldface). The drugs were
attached either on the 50 end or the 30 end of the TFOs to
explore also different sequence contexts.
The aim of the present study was to evaluate if triplex
formation can be used to direct the action of topo II poisons
and induce topo II-mediated DNA cleavage speciﬁcally at the
triplex site. Therefore, the above TFOs were conjugated at
their 30 or 50 end to four VP16 analogs (1, 2, 3 and 4), through
a linker arm (Figure 1). Noteworthy, all analogs are derived
from 40-DMEP (4-b-demethylepipodophyllotoxin) by substi-
tution of the C-4 position, and compounds 1, 2 and 3 are very
similar in structure. Compounds 1 and 3 are active topo II
poisonsthatstabilizethe topoII/DNA cleavage complexesand
increase levels of DNA cleavage, while derivative 2 is inactive
and was used as a control (22). Etoposide analogs were
attached to TFOs via a primary amino group to the terminal
phosphate of a hexaethylene glycol linker (L18,
(OCH2CH2)6PO4
 ) at the end of the TFO, as described pre-
viously in (23). The carboxy derivative 4 was also shown to be
a topo II poison and was linked to the TFO through a ethylene
(L3,(OCH2CH2)PO4
 )orhexaethylene glycol(L18)linker arm.
Finally, two molecules of compound 4 were attached to the
same terminal phosphate of the L18 linker arm, to the 30 end of
the TFOs (16TFO-L18-(4)2 and 20TFO-L18-(4)2), or to a tri-
functional linker arm attached to the phosphate at the 30 end of
the 20TFO (20TFO-L12-(4)2). These latter constructs were
designed to position two molecules of VP16 in the enzyme.
Nucleic Acids Research, 2006, Vol. 34, No. 6 1903The chemical stability of all conjugates and their ability to
formatriple-helical structureintheduplextargetatpH7.2and
37 C was evaluated in a previous study (23).
A triple helix-mediated effect
In the ﬁrst part of our study, the ability of the conjugates to
induce topo II-mediated DNA cleavage was studied.
Figure 2A shows the results obtained with analog 4 attached
to the 16TFO through linker L18 either in 50 (4-L18-16TFO) or
in 30 (16TFO-L18-4). As expected, 4 alone (lane 3) at 50 mM
enhanced topo II-mediated DNA cleavage at several sites (e.g.
e and h). The presence of a 16mer ODN at 1 mM, that differed
in sequence from the 16TFO and was thus unable to bind to the
target, did not modify the topo II cleavage proﬁle (lane 4) or
the one of 4 (lane 5). The triplex-speciﬁc 16TFO, once bound,
mainly protected the triplex site from topo II-mediated DNA
cleavage at sites c+d, for example, and enhanced cleavage at
site b, at 11 bp from the 50 triplex end, and slightly at site e, at
8 bp from the 30 triplex end (lane 6). Furthermore, it did not
inhibit the poisoning by 4 at the other sites (e and h, lane 7).
When the 16TFO was attached at its 50 end to the topo II
poison, DNA cleavage was detected speciﬁcally at site a,
situated 13 bp from the 50 triplex end (lane 8). In contrast,
cleavage at other sites were decreased (site e) or strongly
decrease (sites c+d). Cleavage at site b, which was enhanced
by triplex formation alone, was still observed. When com-
pound 4 was attached to the 30 end of the 16TFO, cleavage
was observed primarily at site f, 14 bp from the 30 triplex end,
and weakly at site g, 18 bp from the 30 end (lane 10). Sites c+d
and e were strongly decreased, while site b, typical of the
triplex structure was maintained. When the 16TFO-L18 and
compound 4 were added unbound (lane 9), the sum of the
cleavage proﬁle of each partner was seen, similar to that
obtained in the presence of L18-16TFO and free 4 (lane 7).
These results suggest that the presence of the triple-helical
structure inﬂuences the cleavage proﬁle of topo II, probably by
altering the local structure of DNA to which the enzyme is
bound, as observed previously with TFO conjugates of amsa-
crine (20). Moreover, the TFO–DMEP conjugate is able to
position the poison speciﬁcally at the end of the triplex and to
stimulate sequence-speciﬁc topo II-mediated DNA cleavage.
The 50 conjugate directed topo II-mediated DNA cleavage
speciﬁcally to the 50 end of the triplex and, likewise, the 30
conjugate to the 30 end. When the sequence-speciﬁc DNA
ligand was increased in length by 4 nt at its 30 end (20mer
20TFO)anditwasattachedto4atits30 endthroughlinkerL18,
triplex-directed cleavage was observed mainly at site g, 14 bp
from the 30 triplex end (Figure 2B lane 7, and Supplementary
Figure 1). As observed for the 16TFO, triplex formation pro-
tected the target site from topo II-mediated cleavage, and
scission at sites c+d was abolished (compare lane 4 to lane
1, and Supplementary Figure 1). With this longer triplex,
cleavage at site e was also strongly decreased even in the
presence of unlinked 4 (lanes 5 and 6). Site b, characteristic
of the triple-helical structure, is present on the 50 side (lane 7).
The addition of the free inhibitor changes the cleavage proﬁle
of the conjugate (lane 9) mainly by adding the cleavage
sites of the free inhibitor, at the exclusion where the conjugate
is bound as it is observed in the presence of the simple triplex,
due to triplex protection from cleavage.
DNA cleavage also was observed on the opposite
oligopurine-rich strand of the target duplex (Figure 2C), stag-
geredby4bp,asexpectedfortopoII-mediatedDNAcleavage.
The same cleavage proﬁle was obtained.
The data are schematized in Figure 3A. Figure 3B sum-
marizes the intensity of topo II-mediated DNA cleavage in
the presence of the 20TFO-L18-4 conjugate. Supplementary
Figure1showstwoexamplesofdenaturinggelsthatwereused
for quantitation. Data are normalized to the cleavage intensity
induced by the free drug (at 1 mM) on a logarithmic scale at
each cleavage site and on both strands of the duplex (in grey
the oligopyrimidine strand, Y and in black the oligopurine
strand, R). The conjugate (ﬁlled bars) is compared to the
20TFO-L18 alone (hatchedbars). Clearly, cleavage is inhibited
by the presence of the triple helix at sites c+d and e, while site
g is strongly enhanced in the presence of the conjugate. The
efﬁcacy of cleavage is comparable on the two strands.
As was the case of the 16mer conjugate, enhanced cleavage
was observed at site a when compound 4 was attached to the
50 end of 20TFO (Figure 3A). This was expected because the
two TFOs share the same 50 end and differ only in length at
the 30 end.
All together, these data indicate that conjugation to a TFO
directs the action of the topo II poison and induces site-speciﬁc
topo II-mediated DNA cleavage.
Design of the conjugates
The choice of the linker arm between the poison and the TFO
was directed by a molecular model obtained by docking the
triple helix in the model of the interaction of topo II with DNA
based on the crystal structure of yeast topo II and Escherichia
coli gyrase (23). This study suggested that the hexaethylene
glycol(L18) was the best suited linker arm.As control ashorter
tether was used, and compound 4 was attached to the 16TFO
through an ethylene glycol (L3), to obtain conjugate 16TFO-
L3-4.Thisconjugate was poorly active (data not shown). Thus,
the hexaethylene glycol appears to be best suited to position
the drug in its active site.
In order to validate the triplex-directed recruitment of topo
II, three other derivatives of VP16 were examined (Figure 1):
compounds 1 and 3, which are active topo II poisons, and
compound 2, which is an inactive analog. These compounds
were attached either to the 30 or 50 end of 16TFO; compound 1
also was attached to the 20mer TFO. The more efﬁcient L18
was used as linker arm between the drug and the TFO. Inter-
estingly, all compounds, 1, 3 and 4, shared the same cleavage
sites, differing only in the intensity of cleavage (data not
shown). The ratio of the cleavage intensity in the presence
ofthe conjugateover the cleavage intensityof the poison alone
is reported on a logarithmic scale as a function of the position
on the target (Figure 3C). It appears that conjugation of the
topo II poisons 4, 1 and 3 to 16TFO and 4 and 1 to 20TFO
directs topo II-mediated DNA cleavage speciﬁcally to the
50 end of the TFO (site a), when attached at the 50 end of
the TFO, and to the 30 end when attached to the 30 end of
the TFO (sites f and g, respectively). The inactive topo II
poison 2, which differs from compound 1 by the presence
of a methyl group on the N-carbamate (Figure 1), remains
poorly active when conjugated and displays a cleavage proﬁle
similar to that of the triplex helix alone. The cleavage efﬁcacy
1904 Nucleic Acids Research, 2006, Vol. 34, No. 6Figure 2. Sequence analysis of topo II-mediated cleavage products in the presence of the 16TFO-L18-4, 4-L18-16TFO and 20TFO-L18-4 conjugates. This analysis
wasmadeonthe96bptargetduplexDNA(50nM)thatwas50 end-radiolabeledontheoligopyrimidine-containingstrand(AandB)orontheoligopurine-containing
strand (C). Cleavage products were resolved on an 8% polyacrylamide gel containing 7 M urea. Adenine/guanine-specific Maxam–Gilbert chemical cleavage
reactions were used as markers (lane G+A). The positions of the cleavage sites are indicated (sites a–h), together with the binding site of the TFO-conjugate.
(A)Targetduplex(lane1)incubatedwithtopoII(0.7U)in theabsence(lane2)orpresenceof50mM4(lane3),1mMODN(lane4),1mMODN+50mM4(lane5),
1 mML 18-16TFO (lane 6), 1 mML 18-16TFO + 50 mM 4 (lane 7), 1 mM 4-L18-16TFO (lane 8), 1 mM 16TFO-L18 + 50 mM 4 (lane 9), 0.5; 1 and 5 mM 16TFO-L18-4
(lanes 10, 11 and 12). (B and C) Target duplex incubated with topo II (0.7 U) in the absence (lane 1) or in the presence of 1 mM (lane 2) or 50 mM 4 (lane 3), 1 mM
20TFO-L18(lane4),1mM20TFO-L18+1mM4(lane5),1mM20TFO-L18+50mM4(lane6),1mM20TFO-L18-4(lane7),5mM20TFO-L18-4(lane8),1mM20TFO-
L18-4 + 50 mM 4 (lane 9).
Nucleic Acids Research, 2006, Vol. 34, No. 6 1905of the 1, 3 and 4 conjugates is comparable at the 30-end, but not
at the 50 end. Furthermore, at the 30 end, the 20mer conjugates
showed better cleavage efﬁcacy compared to the 16mer
conjugates.
The main triplex-induced cleavage site was unexpectedly
situated 13–14 bp from the triplex end (site a, on the 50 end,
and site f, on the 30 end for the 16TFO; Figure 3A). When the
16TFO was increased in length by 4 nt at its 30 end to give the
20TFO, cleavage was induced by all 30 20mer conjugates 4 bp
farther away, at site g. Because both TFOs share the same 50
end, all 50 conjugates stimulated cleavage at the same site a. In
conclusion, whether the VP16 analogs were attached to the 30
orthe 50 end of the TFO, the induced cleavage site was situated
13 or 14 bp from the end of the triplex and was observed
on both strands of the duplex, with different intensities
(Figure 3).
Another point to address is whether two poisons at the same
TFO end induce a more efﬁcient cleavage. Recently, it was
demonstrated that the actions of VP16 at either of the two
scissile bonds appear to be independent of one another, with
each individual drug molecule stabilizing a strand-speciﬁc
nick rather than a double-stranded DNA break (24). Thus,
two drug molecules are necessary to observe cleavage on
both strands. Double conjugates were synthesized
(Figure 1) by covalent linkage of two molecules of 4 to the
L18 linker at the 30 end of both TFOs [16TFO-L18-(4)2 and
20TFO-L18-(4)2] or to two linkers at the 30 end of the 20TFO
[20TFO-L12-(4)2] (23). The three double conjugates induced
Figure 3. Quantification of topo II-mediated DNA cleavage in the presence of TFO–drug conjugates. The analysis was as in Figure 2 and the gels were quantified
afternormalizationrelativetototalradioactivityloaded.(A)Schemeshowingtheenhancedcleavagesiteofeachconjugate:the50 conjugatesaredepictedingreenas
thecorrespondingcleavagesitea;the30 16TFOconjugatesaredepictedinredasthecorrespondingcleavagesitef;the30 20TFOconjugatesaredepictedinblueasthe
corresponding cleavage site g. The other topo II-mediated DNA cleavage sites described in the text are also labeled with letters. (B) Quantification of the specific
cleavagefor20TFO-L18-4onbothstrandscomparedtofree20TFO-L18.Thecleavageintensitywasnormalizedtothecleavageintensityofthefreedrug(at1mM)on
a logarithmicscaleat each cleavage site. Theoligopyrimidine strand is in grayand the oligopurinestrand is in black,the conjugatein filledbars and the 20TFO-L18
alone in hatched bars. (C) Specific cleavage intensities of the conjugates on the oligopyrimidine-containing strand of the duplex (Y). The 50 16TFO conjugates are
depicted in light green (hatched bars 1-L18-16TFO, squares 2-L18-16TFO, horizontal bars 3-Ls-16TFO, vertical bars 4-L18-16TFO), the 50 20TFO conjugates are
depicted in dark green (hatched bars 1-L18-20TFO, vertical bars 4-L18-20TFO), the 30 16TFO conjugates are in red [hatched bars 16TFO-L18-1, squares 16TFO-
L18-2,horizontalbars16TFO-L18-3,verticalbars16TFO-L18-4,crosses16TFO-L18-(4)2]andthe30 20TFOonesareinblue[hatchedbars20TFO-L18-1,verticalbars
20TFO-L18-4, crosses 20TFO-L18-(4)2, dots 20TFO-L12-(4)2].
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efﬁciency slightly lower than the single conjugate (Figure 3C).
In brief, these results indicate that by conjugating a topo II
poison to a TFO and binding of the conjugate to DNA, it is
possible to position the drug at a speciﬁc and chosen site,
and to stimulate topo II-mediated DNA cleavage at this
site. However,the distanceof the cleavage site from the triplex
end, 13 and 14 bp, was unexpected. The longest linker used,
hexaethylene glycol (L18), is not long enough to position
the drug at this distance. This raises the issue of where the
conjugated topo II poison is actually positioned on the DNA.
Positioning of the TFO-poison conjugate
in the ternary complex
Eukaryotic topo II is a homodimeric enzyme, that when bound
to DNA covers  25 bp symmetrically around the cleavage site
(32–34). Furthermore, it is believed that drugs are positioned
in the ternary complex at the topo II/DNA interface at the
cleavage site (35). This has been demonstrated for mAMSA
by the use of a photoactivable derivative that was crosslinked
to DNA at the cleavage site in the presence of topo II (36).
Clearly, the drug moiety of the TFO conjugates cannot realize
this conﬁguration.
To investigate the positioning of VP16 conjugate in relation
to the scissile bonds, we modiﬁed compound 4 by reacting the
40-OH group with an aromatic azido carboxylate. After depro-
tection of 5, the resulting compound 6 was linked to the 30 end
of the TFOs through L18 (16TFO-L18-6 and 20TFO-L18-6,
Figure 4A). Compound 6 is still a topo II poison and shows
the same cleavage pattern as the parent compound 4, but has
weaker activity (Figure 4B, lane 2). Because of the azido
group, this conjugate is able to crosslink to DNA upon irradia-
tion at 365 nm. By using the 20TFO-L18-6 and 16TFO-L18-6
Figure 4. CrosslinkingandDNaseIfootprintingexperiments.(A)Chemicalstructureofconjugatesbearingcompound6.(B)Analysisofcleavage,crosslinkingand
DNase footprinting. The357 bptarget,50 radiolabeled onthe oligopurine strand (lane1)wasincubatedwithtopoII (lane3)and in thepresenceof50 mM6 (lane2),
1mM20TFO-L18-6(lane4)or1mM20TFO-L18+50mM6(lane5),followedbyUVradiationat365nmandpiperidinetreatement(lanes6,7,8and9).Finally,DNase
Iwasaddedaftertriplexformationwith1mMof20TFO-L18-6(lane10),followedbytopoIIaddition(lane11).Adenine/guanine-specificMaxam–Gilbertchemical
cleavage reactions were used as markers (lane G+A). Positions of the cleavage site g and of the crosslinking site CL2 are indicated. Asterisks show the bands
corresponding to cleavage or crosslinking of free compound 6 in the presence of the triplex. Arrows indicate the crosslinking positions of conjugates 16TFO-L18-6
(CL1) and 20TFO-L18-6 (CL2).
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on the DNA in the ternary complex. As depicted in Figure 4B,
conjugate 20TFO-L18-6 induced topo II-mediated DNA clea-
vage at site g, as expected (lane 4). In contrast, the unbound
20TFO in the presence of an excess of 6 protected the triplex
site from cleavage and did not modify the other cleavage sites
(lane 5). Following irradiation and piperidine treatment, cross-
linking was observed in the presence of the conjugate at site
CL2, situated 4 bp from the triplex end (lane 8). This distance
is in agreement with the length of the linker arm, 18 atoms. On
average, 27% of the VP16 analog was crosslinked to the DNA.
Crosslinking was only observed with the azido conjugates
(Supplementary Figure 2). The presence of topo II was not
necessary (Supplementary Figure 2, lanes 3 and 5), indicating
that it is the triplex that positions the drug at this speciﬁc site,
ready to trap the enzyme. In agreement, the cleavage activity
of the enzyme was not necessary, as crosslinking also was
observed in the presence of topo II Y805F (data not
shown), mutated at the catalytic tyrosine necessary for the
formation of the phosphotyrosyl bond involved in the DNA
cleavage reaction. When compound 6 was conjugated to the 30
end of 16TFO (16TFO-L18-6), the crosslinking site again was
observed at 4 bp from the triplex end (Supplementary
Figure 2), site CL1 (Figure 4 lower).
To determine where the enzyme was situated on the DNA
target in the presence of the conjugate, we compared DNase I
footprinting experiments in the presence of the triplex formed
by the conjugates in the absence and presence of topo II.
Figure 4B shows an example of this analysis for conjugate
20TFO-L18-6. Triplex formation protected the DNA from
DNase cleavage at the triplex site (lane 10). In the presence
of topo II, the footprint was extended on the 30 side, to where
the drug was positioned by the TFO (lane 11).
In summary, while the poison was located 4 bp from the
triplex end, topo II-mediated DNA cleavage was induced 10
bp downstream from the site of drug crosslinking. In addition,
topo II was symmetrically located around the cleavage site, as
schematized in Figure 5A. Therefore, the positioning of the
drug at the DNA/topo II interface at the catalytic site is
excluded in this conﬁguration.
DISCUSSION
Results of the present study demonstrate that topo II poisons
can be directed to speciﬁc sequences by conjugating them to a
TFO. In the case of VP16 analogs, DNA cleavage occurred in
14 bp from the end of the triplex site. Optimal cleavage was
observed when the drug was conjugated with the hexaethylene
glycol, L18, linker arm and poisoning required an active drug
analog.
These ﬁndings are similar to those reported for TFO-
conjugated topo I poisons (18,37). However, topo I and II
poisons differ from one another in two signiﬁcant properties.
First, while the conjugated VP16 analogs enhance topo
II-mediated DNA scission when the drug is attached to either
the 30-o r5 0-terminus of the TFO, conjugated camptothecin
derivatives only increase topo I-mediated DNA scission when
they are conjugated to the 30-terminus of the TFO (38). Sec-
ond,whiletheconjugatedtopoIpoisonsinduceDNAcleavage
in the vicinity of the drug, conjugated topo II poisons induce
cleavage more than one turn of the helix away from the triplex
end. The length of the linker arm used to conjugate VP16
analogs to the TFO cannot position the drug at such a distance.
In fact, by using an aromatic azido derivative, compound 6,
we showed that the drug moiety of the conjugate is located at
4 bp from the triplex end (summarized in Figure 5A).
Differences between the site of DNA cleavage and the loca-
tion of the conjugated drug raise the question of where the
poison interacts with the protein. Figure 5B depicts a model
that schematically indicates the possible region of interaction
of the drug with the protein. Since the poison in the conjugate
is located too far away to interact directly at the catalytic site
oftopoII,weproposethatitinteractsintheB0A0 linkerdomain
or at the edge of the A0 binding site, and thus acts by altering
protein conformational changes associated with the topo II
catalytic cycle. In agreement, several mutations in topo II
that increase or decrease the sensitivity of the enzyme to
anticancer drugs are positioned in the linker that joins the
ATPase domain to module B0 and the B0A0 linker (39–43).
Furthermore, our suggestion is in agreement with previous
observations about several possible sites of interaction of
VP16 on human topo IIa. According to previous reports
(41,44), the drug has two binding sites in the protein: one
in the catalytic site and one in the N-terminal, ATPase region
of the enzyme.
Alternatively, it is possible that the ternary complex formed
in the presence of the conjugates is very different from the one
formed by the drug alone. Perturbations in the DNA induced
by the triple-helical structure increased cleavage at speciﬁc
site b (Figure 2). To this point, however, the conjugates
induced cleavage at other speciﬁc sites (f, g and a). Additional
A
B
Figure 5. Model of interaction between TFO-conjugated topo II poisons and
the enzyme. (A) Schematic positioning of the conjugated poison on the DNA
duplexinthepresenceoftopoIIafterthecrosslinkingandDNaseIexperiments.
(B)Potentialregionsofcontactbetweentheconjugatedpoisonandtheenzyme
are encircled in red. The various domains of the homodimer are schematically
shown in red, white, light blue and yellow. The TFO is depicted in blue, the
DNA duplex in black and the poison by a yellow rectangle.
1908 Nucleic Acids Research, 2006, Vol. 34, No. 6sets of experiments suggest that the site of action of the
conjugated poison is also a possible site of action the free
poison on the enzyme. First, crosslinking experiments with
free (i.e. non-conjugated) compound 6 were carried out. We
observed that free compound 6showed very weakcrosslinking
inthepresenceoftopoII(Figure 4B,lane 7).Inthe presence of
the enzyme and the triple helix, crosslinking is enhanced,
and we observed that free compound 6 crosslinked to DNA
10 bp from the respective cleavage site, as in the case of
TFO-conjugated compound 6. This is shown in Figure 4B,
lane 9: the crosslinking sites (asterisks) are shifted compared
to the cleavage sites (lane 5, asterisks). These results suggest
that even in the case of the non-conjugated drug 6 its cleavage
site and its position on the DNA are 10 bp apart. Second,
competition experiments between the drug–TFO conjugates
and well-characterized topo II poisons (VP16) or catalytic
inhibitors (ICRF193) were conducted (Figure 6). A 50-fold
excess of VP16 (500 mM) strongly decreased the crosslinking
efﬁciency of conjugated compound 6 (Figure 6A, lane 8),
suggesting that the TFO-bound drug and VP16 compete for
the same site. ICRF193 is a catalytic inhibitor that traps the
enzyme in its stable clamp form around the DNA (45). This
inhibitor did not compete with the crosslinking efﬁcacy of
conjugated compound 6 (Figure 6B, lane 6), suggesting that
it does not share the same site of action (46).
Taken together, the above results suggest a large and/or
ﬂexible binding site for 40-demethylepipodophyllotoxins on
humantopo IIa that may not be situated strictly in the catalytic
site of the enzyme.
Inconclusion,theuseoftriplehelix-formingODNstotarget
active topo II poisons, such as VP16, may be able to improve
the efﬁcacy of cancer chemotherapy by targeting topo
II-induced cleavage to speciﬁc genes or genomic sequences.
This approach has the potential to reduce the toxicity of VP16
and other topo II-active compounds and to overcome the unde-
sired side effect these drugs, namely the induction of
therapy-related leukaemiaassociated with chromosomal trans-
locations involving MLL(12). Finally, TFO-conjugatedtopoII
poisons represent a class of new tools that may help to unravel
the mechanistic details of the complex process of topo II
poisoning.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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